Recent News

• 06.02.2025 - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
• 05.15.2025 - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
• 05.12.2025 - Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
• 05.06.2025 - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
• 05.05.2025 - Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Recent Filings

• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.06.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.02.2025 - 4 Statement of changes in beneficial ownership of securities